Azithromycin Sulfate for Injection Instructions
Release time:
2020-07-31
Approval Date: March 29, 2007
First Amendment Date: November 13, 2007
Second Amendment Date: October 31, 2014
-dimensional Ruth
Azithromycin Sulfate Instructions
Please read the instructions carefully and use them under the guidance of doctors.
[Drug Name]
Common Name: Azithromycin Sulfate for Injection
Trade Name: Verude
English Name: Azithromycin Sulfate for Injection
Chinese Pinyin: ZhusheyongLiusuan Aqimeisu
[Ingredients] The main ingredient of this product is azithromycin sulfate, and its chemical name is: 9-deoxy -9 α-aza -9 α-methyl -9 α-erythromycin A sulfate.
Chemical Structural Formula:

Molecular Formula: C38H72N2012 H2S04
Molecular Weight: 847.00
[Character] This product is white or almost white loose block or powder.
[indications] 1, for acute pharyngitis caused by Streptococcus pyogenes, acute tonsillitis.
2. For pneumonia caused by Streptococcus pneumoniae, influenza bacillus and Mycoplasma pneumoniae.
3, for chlamydia caused by urethritis and cervicitis.
4. It is used for acute bronchitis and acute attack of chronic bronchitis caused by sensitive bacteria.
5. For skin and soft tissue infections caused by sensitive bacteria.
[Specifications] 0.25g (250000 units) and 0.5g (500000 units) (calculated by C38H72N2012)
[Usage and Dosage] Fully dissolve the product with appropriate amount of water for injection to prepare a solution containing 0.1g per 1ml, then add it to 250ml or 500ml of 0.9 sodium chloride injection or 5% glucose injection, and the final azithromycin concentration is 1.0-2.0 mg/ml for intravenous drip, instillation time: 1 mg/ml, instillation for 3 hours; 2 mg/ml, instillation for 1 hour. For the treatment of community-acquired pneumonia, the adult dosage is 0.5g each time, once a day, for at least 2 consecutive days. Next, azithromycin oral preparation 0.5g/day, 7-10 days of treatment for a course of treatment. The timing of conversion to oral therapy should be determined by the physician based on clinical response. For the treatment of pelvic inflammatory disease, the adult dosage is 0.5g each time, once a day. After 1 day or 2 days of medication, azithromycin oral preparation O.25g is used instead, with 7 days as a course of treatment. The timing of conversion to oral therapy should be determined by the physician based on clinical response. If an anaerobic infection is suspected, an anti-anaerobic drug should be used.
[adverse reactions] occasionally can appear dizziness, headache and fever, rash, joint pain and other allergic reactions, rare anaphylactic shock and angioedema. A few patients may have transient neutropenia and elevated serum aminotransferase.
[taboo] to erythromycin or other macrolide drug allergy is prohibited.
[Precautions] Patients with liver damage should use this product with caution.
[medication for pregnant and lactating women] animal experiments have shown that azithromycin has no effect on the fetus, but it is still lack of experience in the application of human pregnant women, so it is necessary to fully weigh the pros and cons in the application of pregnant women.
There is no information on whether azithromycin can be secreted into breast milk, and the use of azithromycin in lactating women should be considered with caution.
[Children's medication] The dosage and administration method for children under 6 months of age have not been established. Efficacy and safety for the treatment of otitis media in infants less than 6 months of age, community-acquired pneumonia, and pharyngitis or tonsillitis in children less than 2 years of age have not been established.
[Geriatric use] This experiment has not been performed and there are no reliable references.
[Drug Interactions] l. When combined with aminophylline, attention should be paid to monitoring the blood concentration of the latter.
2, and warfarin should pay attention to check the prothrombin time.
3, combined with carbamazepine and digoxin, can increase the blood concentration of carbamazepine and digoxin.
[Overdose] This experiment was not performed and there are no reliable references.
[Pharmacology and Toxicology] Azithromycin is a 15-member ring macrolide, the first variety of nitrogen lactones. Its mechanism of action is the same as that of erythromycin, which mainly binds to the 50s subunit of bacterial ribosome and inhibits RNA-dependent protein synthesis. This product has good antibacterial effect on Streptococcus pyogenes, Streptococcus pneumoniae and influenza bacillus, and also has antibacterial activity on Staphylococcus. This product on Staphylococcus, Streptococcus and other Gram-positive cocci antibacterial effect is slightly worse than erythromycin on influenza bacilli and Moraxella catarrh antibacterial effect than erythromycin 4~8 times and 2~4 times, on a small number of Escherichia coli, Salmonella, Shigella can also have antibacterial effect. This product has good antimicrobial effect on anaerobic bacteria such as digestive streptococcus, mycoplasma pneumoniae and chlamydia trachomatis.
[Pharmacokinetics] This product is widely distributed in the body, and its concentration in various tissues can reach l0 ~ 100 times of the blood drug concentration in the same period. This product has high concentration in macrophages and fibroblasts, the former can transport azithromycin to the site of inflammation. The half-life (tl/2) of azithromycin after a single dose is 35-48 hours, more than 50% of the dose is excreted through the biliary tract in the original form, and about 4.5 within 72 hours after administration is excreted in the original form with urine.
[Storage] Closed and stored in a cool place (not more than 20 ℃).
[Packaging] Glass bottles, 0.25g × 2 bottles/box, 0.25g × 1 bottle/box, 0.25g × 10 bottles/box, 0.5g × 1 bottle/box, 0.5g × 10 bottles/box.
[validity] tentatively 24 months.
[Implementation Standard] WS-359(X-305)-2002(1)(0.25g);WS-359(X-305)-2002(2)(0.5g)
[Approval Document No.] H20000728(0.25g), H20000729(0.5g).
[Production Enterprise]
Enterprise Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Address: No. 58, Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province
Tel: 0579-82661998 (Consultation) 0579-82131973 (Sales)
Fax Number: 0579-82661998 Postal Code: 321075
Website: www.zjjfyy.com.cn
More information
Recently, it was learned from the competent department that the "ERP/MES full-process informatization" project of Jianfeng Pharmaceutical Company has been included in the list of key projects of "integration of industrialization and industrialization" in Jinhua City, and has now entered the publicity period. In order to speed up the in-depth integration of informatization and industrialization, according to the evaluation criteria in Jinhua City's "Several Opinions on Accelerating Informatization Construction" and "Jinhua City Informatization and Industrialization Integration Key Project Management Measures", 148 projects were included in 2017 Jinhua City's "Integration of Industrialization and Industrialization" key projects. The "ERP/MES Full Process Informatization" project of Jianfeng Pharmaceutical Co., Ltd. was finally included in the list after being recommended, material reviewed and expert reviewed by Jinhua Economic and Information Committee. The ERP-level subsystems of ERP/MES full-process informatization project include sales system, procurement system, MRP system, GMPQbD system, connecting UFIDA financial software and HR system. MES-level subsystems include industrial data acquisition and monitoring system, GAMP/MES system, eBPR (electronic batch production record system), cGMP quality assurance system, QC/eBTR(QC process and electronic batch inspection record system), LIMS system, etc. After the construction is completed, the visualization of drug production process and the collection and integration of industrial data will be realized. Realize the electronization of drug production process parameters, electronic batch production and inspection records; the realization of big data integration of industrial data and information will also be in line with the regulatory concept of GMP data integrity and quality traceability to the greatest extent. The establishment of a unified enterprise information platform will eliminate information islands and realize data one.
2020
07-31
The company's first-half profit record high
According to the 15th meeting of the ninth board of directors of the company on August 25, in the first half of 2017, the company achieved a net profit of 240.5357 million yuan, the highest level in half a year's history. In the first half of 2017, the company focused on the general work policy of "grasping trends, precise development, strengthening management, and improving efficiency", grasping the opportunities brought by economic structure optimization and industrial upgrading, strengthening lean production and management improvement internally, and actively exploring externally Develop new opportunities and continue to promote the "three reductions and three improvements" work. Through the joint efforts of all employees of the company, the best semi-annual performance in history has been achieved. As of the end of June 2017, the company's total assets were 4.226 billion yuan and net assets were 2.511 billion yuan; the company achieved total operating income of 1,305.9327 million yuan, an increase of 18.42 percent over the same period last year, and net profit attributable to owners of the parent company was 240.5357 million yuan, an increase of 132.11 percent over the same period last year. Earnings per share are 0.7 yuan. In the second half of the year, the company will continue to focus on the annual business plan, carry out in-depth work of "three reductions and three improvements", further do a good job in internal control, prevent business risks, and further do a good job in safety and environmental protection. we will further develop and improve the complementary relatively diversified main business structure and constantly enhance the company's core competitiveness. The 15th meeting of the 9th board of directors held on August 25 was presided over by Jiang Xiaomeng, chairman of the group company. Four proposals and reports including the 2017 semi annual report and the proposal on the change of the company's accounting policy were deliberated and passed. on the same day, the 12th meeting of the eighth board of supervisors was held,
2020
07-31
General Manager Yu Jianhong to Yunnan Peak to Guide Work
On August 23, Yu Jianhong, general manager of the group company, went to Yunnan Jianfeng cement company for investigation and guidance, and put forward requirements for the key work in the last few months of this year. At the peak of Yunnan Province, Yu Jianhong went deep into the production site to learn more about the current production and operation situation, and convened the middle-level and above management backbones to have in-depth exchanges and discussions with everyone on the problems existing in work efficiency changes, personnel stability, current production and management after the implementation of post optimization and re-organization. Since the beginning of this year, Yunnan's peak production and sales volume, profits and various technological and technical indicators have been relatively ideal. The kiln output in April has also reached the best level since it was put into production. The development and maintenance of the market, the environmental management of the factory area, and the professional quality and mental state of cadres and workers have also been greatly improved. While fully affirming the above achievements, Yu Jianhong pointed out that as the homogenization of the cement market becomes more and more serious, the market changes faster and faster. If we can't recognize the situation and seize the opportunity, enterprises will face more and more problems. In this case, the management backbone should give full play to the role of the backbone, quickly change the management concept, and strive to improve the competitiveness of enterprises. In view of the focus of work in the last four months of this year, Yu Jianhong put forward the following requirements for Yunnan Jianfeng: break the inherent concept of post functions and responsibilities, set up posts and organizational structures around logistics, people flow and capital flow, and cultivate and forge a team that can fight well. To further implement the training of job skills and quality, managers should take the lead in strengthening their own learning and formulate annual, monthly and weekly training plans, through the combination of internal and external training, theory and practice.
2020
07-30
General Manager Yu Jianhong to Yunnan Peak to Guide Work
On August 23, Yu Jianhong, general manager of the group company, went to Yunnan Jianfeng cement company for investigation and guidance, and put forward requirements for the key work in the last few months of this year. At the peak of Yunnan Province, Yu Jianhong went deep into the production site to learn more about the current production and operation situation, and convened the middle-level and above management backbones to have in-depth exchanges and discussions with everyone on the problems existing in work efficiency changes, personnel stability, current production and management after the implementation of post optimization and re-organization. Since the beginning of this year, Yunnan's peak production and sales volume, profits and various technological and technical indicators have been relatively ideal. The kiln output in April has also reached the best level since it was put into production. The development and maintenance of the market, the environmental management of the factory area, and the professional quality and mental state of cadres and workers have also been greatly improved. While fully affirming the above achievements, Yu Jianhong pointed out that as the homogenization of the cement market becomes more and more serious, the market changes faster and faster. If we can't recognize the situation and seize the opportunity, enterprises will face more and more problems. In this case, the management backbone should give full play to the role of the backbone, quickly change the management concept, and strive to improve the competitiveness of enterprises. In view of the focus of work in the last four months of this year, Yu Jianhong put forward the following requirements for Yunnan Jianfeng: break the inherent concept of post functions and responsibilities, set up posts and organizational structures around logistics, people flow and capital flow, and cultivate and forge a team that can fight well. To further implement the training of job skills and quality, managers should take the lead in strengthening their own learning and formulate annual, monthly and weekly training plans, through the combination of internal and external training, theory and practice.
2020
07-31
Spike Pharmaceuticals set out to explore a new sales model
Agency and Terminal Link Production and Chain Cooperation Spike Pharmaceuticals to Explore New Sales Models From August 16 to 21, the 2017 China Pharmaceutical Retail Industry Information Conference (hereinafter referred to as "Xipu Conference") with the theme of "Building a Blueprint-Market Awakening Focusing on Demand" was held in Boao, Hainan. Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, and relevant leaders of Spike Health, pharmaceutical sales company and Spike Pharma pharmacy were invited to attend the event, to create a new sales model "road". This year coincides with the 10th anniversary of the Western Conference. More than 1200 mainstream chain pharmacies, more than 800 brand pharmaceutical industries, more than 100 cross-border affiliated institutions, more than 130 top domestic and foreign capital institutions, more than 60 representatives of authoritative media, and authoritative experts in the industry, with nearly 4000 people gathered in Boao. The meeting combed the context of the pharmaceutical retail industry in the past ten years, discussed the development of the industry in the new decade, and built a new blueprint for the industry. During the meeting, Huang Jinlong led the peak participants to have in-depth exchanges with the organizers of the conference and industry experts on issues such as the impact of national policies such as the brand strategy of enterprises, the role of brand enterprises in the industry, medical reform, prescription outflow, etc. on the original sales mode of pharmaceutical enterprises. He also had extensive contact with pharmaceutical counterparts and terminal chains, listened to front-line sales experience, collected relevant information on terminal chains, and collected market trends of the top 100 chains. In the past ten years, the scale of drug retail sales in China has increased from 143 billion yuan to 337.7 billion yuan, and the chain rate has increased from 35.3 percent to 49.4 percent.
2020
07-31
General Manager Yu Jianhong to Yunnan Peak to Guide Work
On August 23, Yu Jianhong, general manager of the group company, went to Yunnan Jianfeng cement company for investigation and guidance, and put forward requirements for the key work in the last few months of this year. At the peak of Yunnan Province, Yu Jianhong went deep into the production site to learn more about the current production and operation situation, and convened the middle-level and above management backbones to have in-depth exchanges and discussions with everyone on the problems existing in work efficiency changes, personnel stability, current production and management after the implementation of post optimization and re-organization. Since the beginning of this year, Yunnan's peak production and sales volume, profits and various technological and technical indicators have been relatively ideal. The kiln output in April has also reached the best level since it was put into production. The development and maintenance of the market, the environmental management of the factory area, and the professional quality and mental state of cadres and workers have also been greatly improved. While fully affirming the above achievements, Yu Jianhong pointed out that as the homogenization of the cement market becomes more and more serious, the market changes faster and faster. If we can't recognize the situation and seize the opportunity, enterprises will face more and more problems. In this case, the management backbone should give full play to the role of the backbone, quickly change the management concept, and strive to improve the competitiveness of enterprises. In view of the focus of work in the last four months of this year, Yu Jianhong put forward the following requirements for Yunnan Jianfeng: break the inherent concept of post functions and responsibilities, set up posts and organizational structures around logistics, people flow and capital flow, and cultivate and forge a team that can fight well. To further implement the training of job skills and quality, managers should take the lead in strengthening their own learning and formulate annual, monthly and weekly training plans, through the combination of internal and external training, theory and practice.
2020
07-31